Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.
P/E ratio for Alkem Laboratories Limited (ALKEM.NS)
P/E ratio as of 2023: 33.35
According to Alkem Laboratories Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 33.35. At the end of 2022 the company had a P/E ratio of 41.26.
P/E ratio history for Alkem Laboratories Limited from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 33.35 |
| 2022 | 41.26 |
| 2021 | 26.31 |
| 2020 | 20.89 |
| 2019 | 24.67 |
| 2018 | 27.47 |
| 2017 | 36.37 |
| 2016 | 29.55 |
| 2015 | 24.09 |
| 2014 | 42.19 |
| 2013 | 37.20 |
| 2012 | 33.30 |
| 2011 | 38.83 |
| 2010 | 50.05 |
| 2009 | 70.29 |